These findings also reveal the viability of small molecule SARM1 activators, such as vacor and its metabolite VMN, as selective and reversible neuroablative treatments in human neurons for neurological conditions such as spasticity, dystonia and neuropathic pain. Here, SARM1 is linked to Dystonia.